PL2667715T3 - Leczenie zaburzeń spektrum autystycznego z wykorzystaniem kwasu glicylo-l- 2-metyloprolilo-l-glutaminowego - Google Patents

Leczenie zaburzeń spektrum autystycznego z wykorzystaniem kwasu glicylo-l- 2-metyloprolilo-l-glutaminowego

Info

Publication number
PL2667715T3
PL2667715T3 PL12739509T PL12739509T PL2667715T3 PL 2667715 T3 PL2667715 T3 PL 2667715T3 PL 12739509 T PL12739509 T PL 12739509T PL 12739509 T PL12739509 T PL 12739509T PL 2667715 T3 PL2667715 T3 PL 2667715T3
Authority
PL
Poland
Prior art keywords
methylprolyl
glycyl
treatment
glutamic acid
autism spectrum
Prior art date
Application number
PL12739509T
Other languages
English (en)
Inventor
Larry Glass
Michael John Bickerdike
Michael Frederick Snape
Original Assignee
Neuren Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuren Pharmaceuticals Limited filed Critical Neuren Pharmaceuticals Limited
Publication of PL2667715T3 publication Critical patent/PL2667715T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401Proline; Derivatives thereof, e.g. captopril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06Tripeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0085Brain, e.g. brain implants; Spinal cord
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL12739509T 2011-01-27 2012-01-27 Leczenie zaburzeń spektrum autystycznego z wykorzystaniem kwasu glicylo-l- 2-metyloprolilo-l-glutaminowego PL2667715T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161462141P 2011-01-27 2011-01-27
US201161492248P 2011-06-01 2011-06-01
EP12739509.3A EP2667715B1 (en) 2011-01-27 2012-01-27 Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glutamic acid
PCT/US2012/000047 WO2012102832A1 (en) 2011-01-27 2012-01-27 Treatment of autism spectrum disorderes using glycyl-l-2-methylprolyl-l-glutamic acid

Publications (1)

Publication Number Publication Date
PL2667715T3 true PL2667715T3 (pl) 2018-02-28

Family

ID=46581110

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12739509T PL2667715T3 (pl) 2011-01-27 2012-01-27 Leczenie zaburzeń spektrum autystycznego z wykorzystaniem kwasu glicylo-l- 2-metyloprolilo-l-glutaminowego

Country Status (20)

Country Link
US (2) US9708366B2 (pl)
EP (1) EP2667715B1 (pl)
JP (3) JP6348283B2 (pl)
AU (1) AU2012209466C1 (pl)
BR (1) BR112013018898B1 (pl)
CA (1) CA2823218C (pl)
CO (1) CO6791613A2 (pl)
CY (1) CY1119455T1 (pl)
DK (1) DK2667715T3 (pl)
ES (1) ES2641880T3 (pl)
HR (1) HRP20171478T1 (pl)
HU (1) HUE036637T2 (pl)
IL (1) IL227669B (pl)
LT (1) LT2667715T (pl)
PL (1) PL2667715T3 (pl)
PT (1) PT2667715T (pl)
RS (1) RS56461B1 (pl)
SI (1) SI2667715T1 (pl)
SM (1) SMT201700485T1 (pl)
WO (1) WO2012102832A1 (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012102832A1 (en) * 2011-01-27 2012-08-02 Neuren Pharmaceuticals Limited Treatment of autism spectrum disorderes using glycyl-l-2-methylprolyl-l-glutamic acid
WO2013139861A1 (en) 2012-03-20 2013-09-26 Luc Montagnier Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
BR112015012506A2 (pt) * 2012-11-28 2017-07-11 Neuren Pharmaceuticals Ltd tratamento de transtornos do espectro do autismo usando ácido glicil-l-2-metilprolil-l-glutâmico
HRP20201002T1 (hr) * 2013-07-25 2020-10-16 Neuren Pharmaceuticals Limited Neuroprotektivni biciklički spojevi i metode za njihovo korištenje u tretmanu poremećaja autističnog spektra i neurorazvojnih poremećaja
ES2710198T3 (es) 2013-09-23 2019-04-23 Dr August Wolff Gmbh & Co Kg Arzneimittel Tripéptidos antiinflamatorios
CN106659704B (zh) * 2014-06-06 2020-03-10 迪肯大学 治疗孤独症谱系障碍的药物和用途
RU2608444C1 (ru) * 2015-10-02 2017-01-18 Закрытое Акционерное Общество "Алмаз Фарм" Средство для лечения и профилактики расстройств аутистического спектра
JP6694216B2 (ja) 2015-10-14 2020-05-13 学校法人 久留米大学 グレリンを有効成分として含有するレット症候群(rtt)の予防・治療剤
US11972336B2 (en) 2015-12-18 2024-04-30 Cognoa, Inc. Machine learning platform and system for data analysis
WO2017192906A1 (en) * 2016-05-04 2017-11-09 Neurotrope Bioscience, Inc. Methods and compositions for treatment of rett syndrome
CN110192252A (zh) 2016-11-14 2019-08-30 科格诺亚公司 用于评估发育状况并提供覆盖度和可靠性控制的方法和装置
DK3570940T3 (da) 2017-01-20 2024-02-19 Prilenia Neurotherapeutics Ltd Pridopidin til anvendelse i behandling af fragilt x-syndrom
CA3053245A1 (en) 2017-02-09 2018-08-16 Cognoa, Inc. Platform and system for digital personalized medicine
CA3128037A1 (en) * 2019-02-01 2020-08-06 Revivo Therapeutics Nomethiazoles as a treatment for rett syndrome
CA3134521A1 (en) * 2019-03-22 2020-10-01 Cognoa, Inc. Personalized digital therapy methods and devices
EP4009962A4 (en) * 2019-08-05 2023-08-09 Neuren Pharmaceuticals Limited Compositions of trofinetide
IL292617A (en) * 2019-10-28 2022-07-01 Acadia Pharm Inc Preparations for the treatment of Rett syndrome
EP4138880A4 (en) * 2020-04-24 2024-08-07 New York University Use of igf-2 for treatment of epileptic seizures
IT202100004964A1 (it) * 2021-03-03 2022-09-03 Univ Degli Studi Di Bari Aldo Moro Agonisti del recettore fpr2 (formyl peptide receptor 2) e loro uso nel trattamento del disturbo dello spettro autistico.
US11827600B2 (en) * 2021-07-12 2023-11-28 Acadia Pharmaceuticals Inc. Crystalline forms of trofinetide
CN114128672B (zh) * 2021-11-21 2023-04-07 河南省儿童医院郑州儿童医院 一种孤独症大鼠模型的构建方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
DE3169595D1 (en) 1980-11-10 1985-05-02 Gersonde Klaus Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3486459D1 (de) 1983-09-26 1997-12-11 Udo Dr Med Ehrenfeld Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
DK15888D0 (da) 1988-01-14 1988-01-14 Carlsberg Biotechnology Ltd Enzymatisk fremgangsmaade til fremstilling af immunmodulerende pentapeptider samt mellemprodukter til brug ved fremgangsmaaden
SE8803847A0 (sv) 1988-10-27 1990-04-28 Kabigen Ab Neuromodulerande peptid
EP0735894A4 (en) 1993-12-23 1999-08-18 Auckland Uniservices Ltd COMPOSITION AND METHODS FOR IMPROVING THE OUTCOME OF NERVOUS SYSTEM CONDITIONS
CA2190752A1 (en) 1994-05-24 1995-11-30 George N. Cox Modified insulin-like growth factors
JP2001501930A (ja) 1996-10-04 2001-02-13 オークランド ユニサーヴィスィズ リミテッド 神経酵素の調節
AU751217B2 (en) 1998-06-15 2002-08-08 Neuren Pharmaceuticals Limited Regulation of tyrosine hydroxylase
EE05230B1 (et) * 1999-10-26 2009-12-15 Janssen Pharmaceutica N.V. Suukaudselt manustatav galantamiinilahus ja meetod selle valmistamiseks
EP1351976A2 (en) 2000-08-24 2003-10-15 Neuronz Limited Gpe analogs
US8637567B2 (en) 2001-05-24 2014-01-28 Neuren Pharmaceuticals Ltd. Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamic acid
US7605177B2 (en) 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
JP2004536069A (ja) * 2001-05-24 2004-12-02 ニューロンズ・リミテッド Gpe類縁体及びペプチドミメティック
US20070004641A1 (en) * 2001-05-24 2007-01-04 Neuren Pharmaceuticals Limited Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate
US7714020B2 (en) 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
US7863304B2 (en) 2001-05-24 2011-01-04 Neuren Pharmaceuticals Limited Analogs of glycyl-prolyl-glutamate
US7714070B2 (en) 2002-08-27 2010-05-11 Sunoco Chemicals, Inc. In-reactor produced polypropylene blends
AU2005286943A1 (en) 2004-09-20 2006-03-30 Mount Sinai School Of Medicine Use of memantine (NAMENDA) to treat autism, compulsivity, and impulsivity
EP1888618A4 (en) * 2005-05-23 2009-07-15 Neuren Pharmaceuticals Ltd Analogs of glycyl-prolyl-glutamate
EP2001400B1 (en) 2006-03-14 2014-05-07 Neuren Pharmaceuticals Limited Oral formulations of glycyl-2-methylprolyl-glutamate
GB0707127D0 (en) * 2007-04-13 2007-05-23 Zysis Ltd Pharmaceutical compositions
AU2008262387A1 (en) * 2007-06-08 2008-12-18 Massachusetts Institute Of Technology IGF for the treatment of Rett Syndrome and synaptic disorders
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
JP2011529072A (ja) 2008-07-24 2011-12-01 セラヴァンス, インコーポレーテッド 二重作用血圧降下薬
KR20110114664A (ko) 2009-01-16 2011-10-19 메사추세츠 인스티튜트 오브 테크놀로지 자폐 스펙트럼 장애의 진단 및 치료
WO2011146109A2 (en) 2010-05-17 2011-11-24 Mount Sinai School Of Medicine Methods and assays for treating subjects with shank3 deletion, mutation or reduced expression
WO2012102832A1 (en) * 2011-01-27 2012-08-02 Neuren Pharmaceuticals Limited Treatment of autism spectrum disorderes using glycyl-l-2-methylprolyl-l-glutamic acid

Also Published As

Publication number Publication date
US20140147491A1 (en) 2014-05-29
US9212204B2 (en) 2015-12-15
HRP20171478T1 (hr) 2017-11-17
SMT201700485T1 (it) 2017-11-15
IL227669B (en) 2020-06-30
EP2667715A1 (en) 2013-12-04
EP2667715B1 (en) 2017-07-19
CO6791613A2 (es) 2013-11-14
SI2667715T1 (sl) 2017-11-30
HUE036637T2 (hu) 2018-07-30
AU2012209466C1 (en) 2016-06-23
US20150197543A1 (en) 2015-07-16
JP2014508744A (ja) 2014-04-10
AU2012209466B2 (en) 2016-02-25
JP6348283B2 (ja) 2018-06-27
PT2667715T (pt) 2017-10-19
JP6342459B2 (ja) 2018-06-13
AU2012209466A1 (en) 2013-09-05
WO2012102832A1 (en) 2012-08-02
JP2016210808A (ja) 2016-12-15
JP2018138606A (ja) 2018-09-06
BR112013018898B1 (pt) 2021-10-05
JP6640275B2 (ja) 2020-02-05
CY1119455T1 (el) 2018-04-04
CA2823218A1 (en) 2012-08-02
CA2823218C (en) 2021-04-20
RS56461B1 (sr) 2018-01-31
LT2667715T (lt) 2017-11-10
BR112013018898A2 (pt) 2017-04-18
DK2667715T3 (en) 2017-10-23
IL227669A0 (en) 2013-09-30
ES2641880T3 (es) 2017-11-14
US9708366B2 (en) 2017-07-18
EP2667715A4 (en) 2014-07-23

Similar Documents

Publication Publication Date Title
LT2667715T (lt) Autizmo spektro susirgimų gydymas, naudojant glicil-l-2-metilprolil-l-glutamo rūgštį
IL226401A0 (en) Methods for treating disorders related to @fgfBA
EP2717855A4 (en) PROCESSING METHODS
GB201110095D0 (en) Method of treatment
EP2773754A4 (en) Methods of Treatment
ZA201205829B (en) Treatment of respiratory disorders
IL233111A0 (en) Preparations for the treatment of inflammation
GB201202773D0 (en) Compositions for treatment of skin disorders
IL225896A0 (en) Treatment of mecp-2 related disorders
EP2709665A4 (en) TREATMENT OF PSORIASIS
PL395112A1 (pl) Zastosowanie klenbuterolu do leczenia autyzmu
IL239273A0 (en) A method of treating diseases
ZA201308194B (en) Treatment of mastitis
GB201107467D0 (en) Novel treatment of pain
EP2791324A4 (en) PROCESSING METHOD
GB201218263D0 (en) Treatment of autism
GB201101773D0 (en) Treatment of inflammatory disorders
GB201101183D0 (en) Treatment of neurodegenerative disorders
GB201100651D0 (en) Treatment of inflammation
GB201119458D0 (en) Compositions for treatment of sleep disorders
GB201118065D0 (en) Treatment of movement disorders
GB201110602D0 (en) Methods of treatment
GB201109737D0 (en) Methods of treatment
GB201121044D0 (en) Treatment of solutions
IL228973A (en) Oxymetazoline for the treatment of rectal disorders